Pain in desmoid-type fibromatosis: Prevalence, determinants and prognosis value.
Desmoid-type fibromatosis
depression
outcome
pain
quality of life
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 07 2023
15 07 2023
Historique:
revised:
03
02
2023
received:
02
12
2022
accepted:
21
02
2023
medline:
15
5
2023
pubmed:
9
3
2023
entrez:
8
3
2023
Statut:
ppublish
Résumé
The aim of this study is to evaluate the prevalence, determinants and prognostic value of pain at diagnosis in patients with desmoid-type fibromatosis (DF). We selected patients from the ALTITUDES cohort (NCT02867033), managed by surgery, active surveillance or systemic treatments, with pain assessment at diagnosis. Patients were invited to fill QLQ-C30 questionnaire and Hospital Anxiety Depression Scale. Determinants were identified using logistic models. Prognostic value on event-free survival (EFS) was evaluated using the Cox model. Overall, 382 patients were included in the current study (median age: 40.2 years; 117 men). The prevalence of pain was 36%, without significant difference according to first-line treatment (P = .18). In the multivariate analysis, pain was significantly associated with tumor size >50 mm (P = .013) and tumor site (P < .001); pain was more frequent in the neck and shoulder locations (odds ratio: 3.05 [1.27-7.29]). Pain at baseline was significantly associated with poor quality of life (P < .001), depression (P = .02), lower performance status (P = .03) and functional impairment (P = .001); we also observed a nonsignificant association with anxiety (P = .10). In the univariate analysis, baseline pain was associated with poor EFS; the 3-year EFS was 54% in patients with pain compared to 72% in those without pain. After adjustment for sex, age, size and line of treatment, pain was still associated with poor EFS (hazard ratio: 1.82 [1.23-2.68], P = .003). One third of recently diagnosed patients with DF experienced pain, especially those with larger tumors and neck/shoulder locations. Pain was associated with unfavorable EFS after adjustment for the confounders.
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
407-416Informations de copyright
© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020;127:96-107.
Bonvalot S, Ternès N, Fiore M, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol. 2013;20:4096-4102.
Timbergen MJM, Schut AW, Grunhagen DJ, Sleijfer S, Verhoef C. Active surveillance in desmoidtype fibromatosis: a systematic literature review. Eur J Cancer. 2020;137:18-29.
Agresta L, Kim H, Turpin BK, et al. Pazopanib therapy for desmoid tumors in adolescent and young adult patients. Pediatr Blood Cancer. 2018;65:e26968.
Gounder MM, Lefkowitz RA, Keohan ML, et al. Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res. 2011;17:4082-4090.
Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361-370.
Bjordal K, de Graeff A, Fayers PM, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer. 2000;36:1796-1807.
Debaudringhien M, Blay JY, Bimbai AM, et al. Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis. ESMO Open. 2022;7:100578.
Penel N, Bonvalot S, Bimbai AM, et al. Lack of prognostic value of CTNNB1 mutation profile in desmoid-type fibromatosis. Clin Cancer Res. 2022;28:4105-4111.
Colombo C, Belfiore A, Paielli N, et al. β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression. Mol Oncol. 2017;11:1495-1507.
Emori M, Kaya M, Mitsuhashi T, Asanuma H, Yamashita T. Desmoid tumor-associated pain is dependent on mast cell expression of cyclooxygenase-2. Diagn Pathol. 2014;9:14.
Mignemi NA, Itani DM, Fasig JH, et al. Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-β, COX2 and sex steroid receptors. Cancer Sci. 2012;103:2173-2180.
Signoroni S, Frattini M, Negri T, et al. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res. 2007;13:5034-5040. Erratum in: Clin Cancer Res 2008; 14: 4354.
Picariello L, Carbonell Sala S, Martineti V, et al. A comparison of methods for the analysis of low abundance proteins in desmoid tumor cells. Anal Biochem. 2006;354:205-212.
Duhil de Bénazé G, Vigan M, Corradini N, et al. Functional analysis of young patients with desmoid-type fibromatosis: initial surveillance does not jeopardize long term quality of life. Eur J Surg Oncol. 2020;46:1294-1300.
Gounder MM, Mahoney MR, Van Tine BA, et al. Sorafenib for advanced and refractory desmoid tumors. N Engl J Med. 2018;379:2417-2428.
Bouhamama A, Lame F, Mastier C, et al. Local control and analgesic efficacy of percutaneous cryoablation for desmoid tumors. Cardiovasc Intervent Radiol. 2020;43:110-119.
Rigaux P, Lefebvre-Kuntz D, Penel N, “SOS Desmoïde”. Pain burden in desmoid tumor patients: a survey of the French Advocacy Group SOS Desmoid. Bull Cancer. 2015;102:213-216.
Ballatori SE, Hecht JL, Lozano-Calderón SA. A desmoid tumor involving the subscapularis muscle: a case report. JBJS Case Connect. 2019;9:e3.
Goldstein A, Hoang S, Miller DC, Mesfin FB. Extra-abdominal desmoid tumor mimicking cervical spine schwannoma. Cureus. 2018;10:e3145.
Prabhu R, Natarajan A, Shenoy R, Vaidya K. Aggressive fibromatosis (desmoid tumour) of the head and neck: a benign neoplasm with high recurrence. BMJ Case Rep. 2013;2013:bcr2013200156.
Husson O, Younger E, Dunlop A, et al. Desmoid fibromatosis through the patients' eyes: time to change the focus and organisation of care? Support Care Cancer. 2019;27:965-980.
Schut AW, Timbergen MJM, Lidington E, et al. The evaluation of health-related quality of life issues experienced by patients with desmoid-type fibromatosis (the QUALIFIED study)-a protocol for an International Cohort Study. Cancer. 2021;13:3068.
Gounder MM, Maddux L, Paty J, Atkinson TM. Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis. Cancer. 2019;126:531-539.
Gounder M, Ratan R, Alcindor T, et al. Nirogacestat, a g-secretase inhibitor for desmoid tumors. New Engl J Med. 2023;388:898-912.
Pisanu C, Franconi F, Gessa GL, et al. Sex differences in the response to opioids for pain relief: a systematic review and meta-analysis. Pharmacol Res. 2019;148:104447.
Mogil JS, Bailey AL. Sex and gender differences in pain and analgesia. Prog Brain Res. 2010;186:141-157.